当前位置: 首页 > 详情页

Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China [4]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China [5]Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Peoples R China [6]Yunnan Univ, Kunming, Yunnan, Peoples R China [7]Gen Surg Clin Med Ctr Yunnan Prov, Kunming, Peoples R China [8]Sichuan Univ, West China Hosp, Dept Clin Nutr, Chengdu, Peoples R China [9]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Comprehens Oncol, Beijing, Peoples R China [10]Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning, Peoples R China
出处:
ISSN:

关键词: Cachexia CRC ECOG-PS Systemic inflammation

摘要:
BackgroundThe development and progression of cancer cachexia are connected to systemic inflammation and physical performance. However, few relevant studies have reported the survival outcomes prediction of systemic inflammation and physical performance in patients with colorectal cancer (CRC) cachexia. This study investigated the prognostic prediction value of systemic inflammation and performance status in patients with CRC cachexia.MethodsThis multicentre cohort study prospectively collected 905 patients with CRC (58.3% males, 59.3 +/- 11.5 years old). Cancer cachexia was diagnosed according to the 2011 Fearon Cachexia Diagnostic Consensus. The prognostic value of systematic inflammatory indicators was determined using the area under the curve, concordance index, and multivariate survival analysis. Performance status was evaluated with Eastern Coopertive Oncology Group performance score (ECOG-PS). Survival data were analysed using univariate and multivariate Cox regression analyses.ResultsThe area under the curve, concordance index and survival analysis showed that C-reactive protein (CRP), lymphocyte to CRP ratio (LCR) and CRP to albumin ratio (CAR) were more stable and consistent with the survival of patients with CRC, both in non-cachexia and cachexia populations. Among patients with CRC cachexia, high inflammation [low LCR, hazard ratio (HR) 95% confidence interval (95% CI) = 3.33 (2.08-5.32); high CAR, HR (95% CI) = 2.92 (1.88-4.55); high CRP, HR (95% CI) = 3.12 (2.08-4.67)] indicated a worse prognosis, compared with non-cachexia patients [low LCR, HR (95% CI) = 2.28 (1.65-3.16); high CAR, HR (95% CI) = 2.36 (1.71-3.25); high CRP, HR (95% CI) = 2.58 (1.85-3.60)]. Similarly, among patients with CRC cachexia, high PS [ECOG-PS 2, HR (95% CI) = 1.61 (1.04-2.50); ECOG-PS 3/4, HR (95% CI) = 2.91 (1.69-5.00]) indicated a worse prognosis, compared with patients with CRC without cachexia [ECOG-PS 2, HR (95% CI) = 1.28 (0.90-1.81); ECOG-PS 3/4, HR (95% CI) = 2.41 (1.32-4.39]). Patients with CRC cachexia with an ECOG-PS score of 2 or 3-4 and a high inflammation had a shorter median survival time, compared with patients with an ECOG-PS score of 0/1 and a low inflammation.ConclusionsThe systemic inflammatory markers LCR, CAR and CRP have stable prognostic values in patients with CRC. The ECOG-PS may be an independent risk factor for CRC. Combined evaluation of systemic inflammation and ECOG-PS in patients with CRC cachexia could provide a simple survival prediction.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 医学
小类 | 1 区 老年医学 1 区 医学:内科
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 老年医学 1 区 医学:内科
JCR分区:
出版当年[2021]版:
Q1 GERIATRICS & GERONTOLOGY Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL Q1 GERIATRICS & GERONTOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China [4]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, Beijing, Peoples R China [10]Guangxi Med Univ, Sch Preclin Med, Dept Immunol, Nanning, Peoples R China [*1]Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Key Laboratory of Cancer FSMP for State Market Regulation, 10 Tie Yi Road. Beijing 100038, China. [*2]Department of Immunology, School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院